Merck: Ever More Willing to Share
The famously insular Merck & Co. has embarked on a late-stage feeding frenzy, ceding an unprecedented amount of marketing control to its new partners in return for marketing rights. Three of Merck's next four drug introductions will likely be co-promotions: ezetimibe/simvastatin (Vytorin), with Schering-Plough, gaboxadol, from H. Lundbeck, and now muraglitazar, from Bristol-Myers Squibb.
You may also be interested in...
Having kept out of the race to develop a vaccine, Novartis has joined efforts with a collaboration using the AAV gene therapy vector.
Philips has added a Clinical Trials Accelerator functionality to the cloud-based HealthSuite digital platform, underlining its role in securely managing and collecting device and personal data for use by third-party clients seeking to build health care solutions.
Bavencio’s Survival Benefit Confirmed In Front-Line Maintenance Therapy For Advanced Urothelial Cancer
Further details of Merck KGaA/Pfizer-funded JAVELIN Bladder 100 study presented at this year’s ASCO confirm avelumab’s survival benefit when used as front-line maintenance therapy in patients with advanced urothelial cancer that has not progressed following initial chemotherapy.